|[December 04, 2013]
Research and Markets: The Global Predictive Breast Cancer Gene Testing Market to Grow Significantly, From US$422m in 2011 to US$1 Billion by 2018 at a CAGR of 14%
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/qms24g/medipoint)
has announced the addition of the "MediPoint:
Predictive Breast Cancer Gene Testing - Global Analysis and Market
Forecasts" report to their offering.
Myriad Losing Grip on Predictive Breast Cancer Gene Testing Market
The US represents the largest predictive breast cancer gene testing
market, and Myriad Genetics' intellectual property rights mean that
opportunities for new market entrants are restricted to non-BRCA
testing, which constitutes only 1% of the region's gene testing market.
However, 2015-2018 will mark the expiry of several patents and licenses
relating to Myriad Genetics' flagship BRAC Analysis gene test, opening
up competition in the US.
Myriad Genetics' patents are less enforced abroad, and new opportunities
are already present for BRCA tests in Europe. Dr. Thompson states:
Myriad Genetics hopes to expand in Europe, but the market consists o
many players who are currently offering tests, while infringing Myriad
Genetics' patents. The last 12 months have seen DNA Sequencer
manufacturers make significant acquisitions of niche genetic testing
laboratories, in an apparent move to compete in the clinical genetic
testing market, representing a potential threat to Myriad Genetics.
China offers the greatest breast cancer gene testing market
opportunities, with the large population suffering rising numbers of
breast cancer cases as lifestyles change. The country's relatively
advanced healthcare industry allows for significant growth in genetic
testing processes, whereas Brazil and India hold limited opportunities
due to a lack of affordable healthcare. However, a great need arises for
low-cost gene testing at a community level in India, based on a breast
cancer mutation prevalent in the Indian population.
This report provides information on the breast cancer gene testing
market, including diagnosis rates, patient segmentation, treatment
rates, procedure volumes, average selling prices, and market values over
a 10 year period (2009-2018).
-Centogene AG (Centogene Rostock GmBH)
-Diagnosticos da America SA (DASA)
-Navigenics (now Life Technologies)
-The Doctors Laboratory Ltd.
For more information visit http://www.researchandmarkets.com/research/qms24g/medipoint
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To Technology News's Homepage ]